2型糖尿病患者心血管安全性临床试验中使用的肾脏终点指标综述及其在初级保健中的重要性。
Review of the renal endpoints used in cardiovascular safety clinical trials in type 2 diabetes mellitus patients and their importance in primary care.
作者信息
Górriz Jose Luis, Cos Claramunt Francesc Xavier, Duque Natalia, Matali Arantxa
机构信息
Nephrology Department, Hospital Clínico Universitario, INCLIVA, Valencia, Spain; Universidad de Valencia, Valencia, Spain; Grupo Español de Estudio de Nefropatía Diabética (GEENDIAB), Spain.
Innovation and Health in Primary Care Barcelona City, Gerencia Barcelona Ciutat, Institut Català de la Salut, Barcelona, Spain; Universidad Autónoma de Barcelona, Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; Primary Care Diabetes Europe (PCDE), Antwerpen, Belgium.
出版信息
Prim Care Diabetes. 2019 Dec;13(6):485-494. doi: 10.1016/j.pcd.2019.07.001. Epub 2019 Aug 7.
Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes mellitus (T2DM). Furthermore, CKD confers a considerable increase in the risk of cardiovascular (CV) morbidity and mortality. In line with the need to improve knowledge in this field, this article aims to describe the renal endpoints used in the different cardiovascular outcome trials (CVOTs). The objective is to better know the renal variables used in the different CVOTs in order to optimize the implementation of advances in the prevention of progressive diabetic kidney disease in patients with T2DM in clinical practice.
慢性肾脏病（CKD）是2型糖尿病（T2DM）最常见的并发症之一。此外，CKD会显著增加心血管（CV）发病和死亡风险。为满足提高该领域认知的需求，本文旨在描述不同心血管结局试验（CVOTs）中使用的肾脏终点指标。目的是更好地了解不同CVOTs中使用的肾脏变量，以便在临床实践中优化对T2DM患者预防糖尿病肾病进展方面进展的应用。
Zotero 插件